Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 14/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 14/20 | 0.70 |
| ▸ | FLT1 | P17948 | 11/20 | 0.70 |
| ▸ | FLT4 | P35916 | 11/20 | 0.70 |
| ▸ | KDR | P35968 | 11/20 | 0.70 |
| ▸ | SRC | P12931 | 3/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | CSK | P41240 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470677 | 0.86 | FGFR1 (0.72) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL22144559 | 0.83 | FGFR1 (0.95) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL19848922 | 0.83 | FGFR1 (0.80) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| Pd-173074 SCHEMBL29828472 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| Pd-173074 SCHEMBL177946 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL31648262 | 0.82 | FGFR1 (0.76) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL3479994 | 0.82 | FGFR1 (0.87) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL30737861 | 0.81 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL2470675 | 0.81 | FGFR1 (0.85) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL31648009 | 0.80 | FGFR1 (0.78) | FGFR1FGFR2FGFR4FGFR3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140148483-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2711433-A1 | METHOD FOR PREDICTING EFFECTIVENESS OF ANGIOGENESIS INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| EP-2281901-A2 | Anti-tumour pharmaceutical composition with angiogenesis inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148483-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | FGFR1 48/4885FGFR2 135/4885FGFR4 151/4885 |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | VEGFA, EDF1, HDGF | FGFR1 81/4885FGFR2 273/4885FGFR4 107/4885 |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | FGFR1 48/4885FGFR2 135/4885FGFR4 151/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | FGFR1 87/4885FGFR2 220/4885FGFR4 70/4885 |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | FGFR1 48/4885FGFR2 135/4885FGFR4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.